<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30290661</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>23</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>23</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>40</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?</ArticleTitle>            <Pagination>                <MedlinePgn>e12690</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012690</ELocationID>            <Abstract>                <AbstractText>Different biological subtype breast cancers respond differently to neoadjuvant chemotherapy, but it is unknown whether neoadjuvant or adjuvant chemotherapy leads to different long-term survival in each specific subtype although equal outcomes have been reported in general population. This study sought to clarify whether the selection of either neoadjuvant or adjuvant chemotherapy was linked to a differential survival benefit based on breast cancer subtypes.A prospectively maintained breast cancer database was queried from 2000 to 2008. All patients with a diagnosis of stage II and III breast cancer who received neoadjuvant or adjuvant chemotherapy were identified, only patients receiving docetaxel and epirubicin (TA) regimen were included. Patients were divided according to the administration of neoadjuvant or adjuvant chemotherapy. The biological subtypes were determined by immunohistochemical tests. The outcomes between neoadjuvant and adjuvant chemotherapy were compared in each different subtype. Kaplan-Meier curves were generated, and the Cox model was used to estimate the association between death risk and chemotherapy timing while adjusting for potentially confounding factors. P values &lt; .05 were considered statistically significant.Of the 406 patients included, 201 (49.5%) received neoadjuvant chemotherapy, and 205 (50.5%) received an adjuvant TA regimen. Patients with the HER2+ and TNBC subtypes showed significantly higher pCR rates than patients with luminal types (P &lt; .05). In general population, the neoadjuvant and adjuvant chemotherapy groups showed little survival variance (HR=1.15, 95% confidence interval (CI) .69-1.91, P=.60). In luminal B-like patients, neoadjuvant chemotherapy led to worse overall survival (OS) than adjuvant therapy (HR=2.92, 95%CI 1.20 to 8.31, P = .02). In patients with the HER2+ subtype, neoadjuvant treatment corresponded to better OS (HR = .10, 95%CI .02-.58, P = .01). In contrast, patients with luminal A-like (HR = 1.14, 95%CI .53-2.43, P = .74) and TNBC disease (HR = 1.00, 95%CI .27-3.73, P = &gt;.99) who underwent neoadjuvant chemotherapy showed equivalent OS when compared to patients undergoing adjuvant therapy.Neoadjuvant versus adjuvant chemotherapy results in a disparate impact on overall survival among patients with variant subtype breast cancer. When neoadjuvant chemotherapy was given, luminal B-like patients showed worse outcome, while patients with HER2+ disease had better OS. Prospective studies are necessary to determine and optimize the timing of chemotherapy for breast cancers with different molecular backgrounds.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Houpu</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Lixin</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Surgery, Peking University People's Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Shu</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cao</LastName>                    <ForeName>Yingming</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tong</LastName>                    <ForeName>Fuzhong</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Peng</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Bo</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cheng</LastName>                    <ForeName>Lin</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Miao</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Hongjun</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xie</LastName>                    <ForeName>Fei</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guo</LastName>                    <ForeName>Jiajia</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Siyuan</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Peng</LastName>                    <ForeName>Yuan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Peking University People's Hospital Breast Center.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D064888">Observational Study</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>15H5577CQD</RegistryNumber>                <NameOfSubstance UI="C067311">docetaxel</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>3Z8479ZZ5X</RegistryNumber>                <NameOfSubstance UI="D015251">Epirubicin</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015251" MajorTopicYN="N">Epirubicin</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018734" MajorTopicYN="N">Genes, erbB-2</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30290661</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000012690</ArticleId>            <ArticleId IdType="pii">00005792-201810050-00075</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>